News

Autonomix Medical, Inc. Drives Towards U.S. Pivotal Trial with Appointment of Vice President, Regulatory Affairs and Quality

Autonomix Medical, Inc. Biotech/Med Device executive Continued efforts to build team and infrastructure required to support clinical and regulatory initiatives…

1 year ago

HWH International Inc. Provides Updates on Hapi Cafe Business

BETHESDA, MD, Dec. 19, 2024 (GLOBE NEWSWIRE) -- HWH International Inc. (“HWH” or the “Company”) (Nasdaq: HWH) is pleased to…

1 year ago

Gelteq Appoints Dr. Paul Wynne as Chief Scientific Officer to Propel Innovative Ingestible Gel Technology

NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a global biotechnology company…

1 year ago

Prenetics’ IM8 Announces Collaboration with Mayo Clinic to Develop New Line of Premium Supplements

Collaboration to Focus on Nutrition, Cellular Rejuvenation, Protein, Collagen and Overall Wellness IM8, a New Premium Supplements Brand, Launched Officially…

1 year ago

TOMI Environmental Stands Ready to Protect Public Health Amidst H5N1 Bird Flu California State Emergency

FREDERICK, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in…

1 year ago

ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21

FREMONT, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative…

1 year ago

Aphaia Pharma to Participate in Panel Discussion at the 1st Annual BioPharma Obesity Innovation Forum in San Francisco

ZUG, Switzerland and SAN JUAN, Puerto Rico and TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage company…

1 year ago

Marker Therapeutics Announces $16.1 Million Private Placement

Strategic financing supports clinical advancement in Phase 1 APOLLO study investigating MT-601 in patients with lymphoma who relapsed after anti-CD19…

1 year ago

Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma

APOLLO study investigating MT-601 in patients with relapsed lymphoma: 78% of patients achieved objective response rates, with 44.4% demonstrating complete…

1 year ago

IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer

Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001 Vertical integration…

1 year ago